UPCC 29925 A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy with LY4337713 in Adults with FAP-Positive Solid Tumors (FiREBOLT) (FiREBOLT)

Investigational Radioligand Therapy for FAP-Positive Solid Tumors

Enrolling By Invitation
18 years or above
All
Phase 1
241 participants needed
1 Location

Brief description of study

This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Cholangiocarcinoma
  • Age: 18 years or above
  • Gender: All

Inclusion Criteria:

  • Must have clinical or imaging evidence of fibroblast activation protein (FAP) expression per local assessment
  • Must have histologically or cytologically confirmed diagnosis of one of the following
    • Adenocarcinoma of the pancreas
    • Hormone receptor (HR)-positive human epidermal growth factor 2 (HER2)-negative breast cancer
    • HER2-positive breast cancer
    • Triple negative breast cancer (TNBC)
    • Platinum-resistant or refractory ovarian cancer (including ovarian carcinosarcoma)
    • Other solid tumors
      • Gastric cancer (adenocarcinoma)
      • Colorectal cancer (CRC)
      • Esophageal cancer (squamous cell carcinoma or adenocarcinoma)
      • Cholangiocarcinoma
  • Must have received prior treatments as indicated below:
    • Phase 1a
      • Adenocarcinoma of the pancreas: Participants must have received at least 1, but no more than 2 prior regimens for locally advanced unresectable or metastatic disease.
      • HR-positive HER2-negative breast cancer: Participants must have received less than or equal to (≤)5 prior lines of treatment for advanced or metastatic disease, which must include a cyclin-dependent kinase 4/6 inhibitor.
      • HER2-positive breast cancer: Participants must have received at least 2 lines of HER2-targeted therapy, which should include at least 1 antibody-drug conjugate (ADC) for metastatic disease (if locally available).
      • TNBC: Participants must have received at least 2 lines of therapy for metastatic disease.
      • Platinum-resistant or refractory ovarian cancer: Participants must have received or after at least 1 platinum-based therapy.
      • Other solid tumors (gastric cancer, CRC, esophageal and cholangiocarcinoma): Participants must have received greater than or equal to (≥)1 prior line of systemic therapy for advanced or metastatic disease; including prior line(s) in combination with immunotherapy or vascular endothelial growth factor inhibitor.
    • Phase 1b:
      • Participants must have advanced or metastatic solid tumors and have received ≥1 prior line of therapy.
  • Must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to

    1.

  • Measured creatinine clearance ≥60 milliliters per minute (mL/min)

Exclusion Criteria:

  • Have known active central nervous system (CNS) metastases or carcinomatous meningitis.
  • Have significant cardiovascular disease
  • Have prolongation of the corrected QTcF >470 milliseconds (msec) during screening. QTcF is calculated using Fridericia's Formula: QTcF = QT/(RR0.33)
  • Have evidence of ongoing and untreated urinary tract obstruction
  • Had previous hemi- or total-body radiation.
  • Had previous adoptive T-cell therapy (e.g., chimeric antigen receptor T-cell [CAR-T therapy, T-cell receptor [TCR] therapy, etc.)
  • Unable to lie flat during, or otherwise tolerate, single photon emission computed tomography (SPECT), positron emission tomography (PET), computed tomography (CT) or magnetic resonance imaging (MRI).

This study investigates the safety and effects of an investigational radioligand therapy in adults with advanced or metastatic solid tumors that have high levels of fibroblast activation protein (FAP). The study aims to understand how the investigational therapy interacts with FAP. The purpose of this study is to evaluate the safety, side effects, and how the body processes the therapy, including its absorption, breakdown, and elimination.

Participants will undergo various procedures to monitor the effects of the investigational therapy. This includes regular blood tests to measure how much of the therapy is in the bloodstream and imaging tests to observe its impact on tumors. These procedures help researchers understand how the therapy works in the body and its potential benefits for treating FAP-positive cancers.

  • Who can participate: Adults with advanced or metastatic solid tumors expressing fibroblast activation protein (FAP) can participate. They must have specific cancers such as pancreatic adenocarcinoma, certain breast cancers, ovarian cancer, or other solid tumors, have undergone prior treatments, and maintain good performance status.
  • Study details: Participants will receive the investigational therapy and undergo blood tests and imaging to monitor its effects. Regular assessments will evaluate the therapy's impact on cancer and overall health.
  • Study timelines: The study will last about 5 years.
Updated on 07 Jul 2026. Study ID: 25-2128
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator